C. Gary Marshall

C. Gary Marshall

Company: Repare Therapeutics

Job title: Senior Director of Project Leadership


Progress in PKMYT1 Inhibition: RP-6306 2:30 pm

• PKMYT1 is synthetic lethal with CCNE1 amplification and FBXW7 deleterious mutation and represents a unique targeting opportunity in patients with significant unmet need • RP-6306 is a potent and selective inhibitor of PKMYT1 that is safe and efficacious in models of CCNE1 amplification and FBXW7 loss • Combination of RP-6306 with standard of care…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.